Compare Halliburton Company (HAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs State Street SPDR S&P Biotech ETF — how do they compare? Halliburton Company trades at $33.21 (market cap $29.33B), while State Street SPDR S&P Biotech ETF trades at $153.72. The key difference: Halliburton Company pays a 1.94% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Halliburton Company nearer its low. Which is the better fit depends on your goals.
| HAL | XBI | |
|---|---|---|
Market Cap | $29.33B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $42.98 | $164.28 |
52-Week Low | $20.50 | $85.16 |
Enterprise Value | $35.41B | — |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $35.56, up 0.97% on the day, with a bullish technical signal supported by moving averages. The company shows solid fundamentals with a P/E of 19.46 and ROE of 14.56%, though net income declined to $1.28B in 2025. Recent contract wins with Aramco in Saudi Arabia and TotalEnergies in Suriname highlight growth opportunities, while analyst consensus is strongly bullish with a $44.78 price target.
Outlook remains positive due to strategic contracts and oil price support from geopolitical tensions, but risks include Middle East volatility and cost pressures. The stock offers value with earnings beats and institutional backing, though investors should monitor debt levels and execution on new projects.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
